2023-05-04 17:14:58 ET
- Celldex press release ( NASDAQ: CLDX ): Q1 GAAP EPS of -$0.62.
- Revenue of $1M (-94.2% Y/Y).
- Cash, cash equivalents and marketable securities as of March 31, 2023 were $278.4 compared to $305.0 million as of December 31, 2022.
- Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at March 31, 2023 are sufficient to meet estimated working capital requirements and fund planned operations through 2025, which include our ongoing Phase 1b studies in urticaria and prurigo nodularis and our ongoing and planned Phase 2 studies in CSU, CIndU and EoE.
For further details see:
Celldex GAAP EPS of -$0.62, revenue of $1M